Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Bullboard (TSXV:ARCH)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by TheBearInTheWoodson Mar 08, 2022 8:43pm

RE:RE:first-ever signal towards validating Dipeptidase-1

Nice to see shares going into stronger hands before the next trial 
175
Discussion
Comment by 2019champson Mar 08, 2022 5:06pm

RE:RE:first-ever signal towards validating Dipeptidase-1

Covid isn't going away and this isn't a covid play but ok. Good luck
125
Discussion
Comment by GoldenArmon Mar 08, 2022 1:58pm

RE:first-ever signal towards validating Dipeptidase-1

With Covid going bye-bye these stocks may not get much attention. I'm out fo now.
134
Discussion
Post by C10H12N2on Mar 06, 2022 1:06pm

@Riverfolk

CEO.CA | #arch Arch Biopartners Inc. (ARCH.V)
196
Post by Riverfolkon Mar 04, 2022 9:37pm

first-ever signal towards validating Dipeptidase-1

Phase II results provide a first-ever signal towards validating Dipeptidase-1’s role in the mechanism of action of organ inflammation in humans   These Phase II results provide key human data ...more  
201
Discussion
Post by Riverfolkon Mar 04, 2022 9:32pm

Arch - Fully Funded Phase III Human Trial Approved

LSALT Peptide has completed an international Phase II trial targeting organ inflammation often experienced in hospitalized COVID-19 patients. LSALT peptide has recently been accepted into the Canadian ...more  
165
Comment by futuregainson Mar 01, 2022 10:54am

RE:University of Calgary Article

Brilliant article. Worth the read.
121
Discussion
Post by Betteryear2on Feb 14, 2022 7:35am

Receives Approval from Health Canada to Amend Protocol

TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug ...more  
199
Post by Arbourmarkon Feb 07, 2022 5:29pm

News Coming

I have a feeling that good news is coming very soon! 
176
Comment by GoldenArmon Feb 03, 2022 3:59pm

RE:Metablok - A pathway to an unmet 20 billion market

Good repaort Riverfolk. I've been stupid busy lately and haven't posted too much. I think this company is a no brainer because of the potential of the drug  for not just covid but other ...more  
161
Discussion
Post by Riverfolkon Feb 03, 2022 9:57am

Metablok - A pathway to an unmet 20 billion market

Recently Arch Biopartners released a glimpse of the human data waiting on publication from a third party, that should be expected shortly. This data was further validated by CATCO when they sponored a ...more  
276
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities